The global medical tourism market is forecast to almost double from $109 billion in 2026 to more than $215 billion by 2030. Western Europe is expected to be its fastest-growing region, while orthopaedic treatment alone could become a $28.7 billion international market. For UK patients confronting high private healthcare prices and long NHS waits, the message is increasingly clear: travelling for high-quality treatment is moving rapidly into the healthcare mainstream.
For decades, the phrase “medical tourism” conjured up images of cosmetic surgery in exotic locations.
That picture is becoming seriously outdated. A global market analysis from The Business Research Company (TBRC) published in August 2026 forecasts that international and domestic medical travel will become one of the world’s fastest-growing areas of healthcare over the remainder of this decade.
The figures are striking. The global medical tourism market was valued at $91.98 billion in 2025 and is expected to reach $109.34 billion during 2026. By 2030, TBRC forecasts a market worth $215.15 billion.
That represents annual compound growth of 18.4% between 2026 and 2030. Put another way, in just four years the market is expected to become almost twice as large as it is today. And one of the most significant developments for British patients is where that growth is happening.
Western Europe moves centre stage
Western Europe is identified by the report as the world’s fastest-growing medical tourism region.
By 2030, its market is forecast to be worth $56.91 billion, behind Asia-Pacific at $67.9 billion and North America at $63.21 billion, but substantially ahead of Eastern Europe, South America, the Middle East and Africa.
This matters because cross-border healthcare does not necessarily mean travelling halfway around the world. For UK patients, some of Europe’s leading private hospitals can be reached via MMG in little more time than it takes to travel between major British cities.
The report identifies affordability as one of the strongest forces driving the market. Patients living in high-cost healthcare systems are increasingly prepared to travel to obtain high-quality treatment at substantially lower prices. At the same time, hospitals in destination countries are developing bundled packages combining treatment with the additional services required by international patients.
Technology is narrowing the gap further. Advanced imaging, robotic surgery and sophisticated surgical techniques are no longer confined to a small group of countries. International accreditation and increasingly consistent clinical standards are also making it easier for patients to identify reputable providers outside their domestic healthcare system.
This is particularly relevant to MMG’s model. Rather than asking British patients simply to find an unfamiliar hospital somewhere overseas, My Medical Gateway provides access to selected Accredited Healthcare Providers across Europe through a single digital marketplace, with transparent Treatment Packages and a structured patient journey.
The distinction is important. The future of cross-border healthcare is unlikely to be built around patients searching the internet for a cheap operation. It will increasingly depend upon platforms which allow consumers to compare credible providers, understand prices and navigate the entire treatment process.
Ageing populations and the orthopaedic opportunity
TBRC identifies ageing populations as another major driver of international healthcare demand. People are living longer, but longer lives inevitably create greater demand for treatments that maintain mobility, independence and quality of life. That makes the report’s forecasts for orthopaedic treatment particularly interesting.
The global medical tourism market for orthopaedics alone is forecast to reach $28.72 billion by 2030. That category encompasses joint replacements, spinal surgery, arthroscopy, fracture repair and sports injury treatment — precisely the kinds of procedures where patients may have considerable freedom over when and where they receive treatment.
Other sectors are expanding even faster. International cosmetic treatment is forecast to reach $43.68 billion by 2030, dental treatment $37.55 billion, cardiovascular treatment $32.45 billion and cancer treatment $23.38 billion. The incremental growth expected before 2030 is enormous. Cosmetic treatment alone is forecast to add $24.06 billion in market value, dental treatment $21.06 billion and cardiovascular treatment $19.01 billion.
Yet the report also identifies the obstacles preventing many more people from travelling. These include uncertainty about standards between countries, limited insurance coverage and the different regulatory and legal systems governing healthcare.
Those concerns are entirely understandable. Healthcare is not like booking a hotel. Patients need confidence about who is treating them, where they will be treated, what their package includes, what happens before they travel and what support exists afterwards.
That is why MMG has developed a robust contractual and governance framework specifically designed for cross-border healthcare. Accredited Healthcare Providers joining the MMG marketplace must agree to defined standards and contractual obligations governing their participation, while patients enter into a clear Patient Treatment Contract setting out the respective responsibilities surrounding their treatment.
This framework is designed to replace much of the uncertainty traditionally associated with arranging medical treatment independently overseas. It establishes clear rules around the treatment journey, pricing and payments, clinical assessment, patient information, cancellations and refunds, complaints, post-treatment support and the responsibilities of the healthcare provider.
Crucially, MMG does not simply introduce a patient to an overseas hospital and then disappear from the process. Its model is designed around an independently governed, end-to-end healthcare service supporting the patient from the initial search and selection of a provider through diagnostics, booking and treatment to post-operative support and follow-up.
As international healthcare expands, trust and accountability will become every bit as important as price. Solving those problems may ultimately prove more important than simply identifying the cheapest operation — and it is precisely why MMG has invested so heavily in creating a structured legal and governance framework around the patient’s cross-border treatment journey.
AI is already transforming how MMG patients choose healthcare
Perhaps the most interesting technological trend identified by TBRC is artificial intelligence. The report highlights the emergence of AI-powered medical travel technology capable of matching patients with hospitals and treatments according to their requirements, budget and preferred destination.
This is not simply a glimpse of where cross-border healthcare might be heading. MMG is already implementing AI technology across its digital platform to make finding, comparing and accessing treatment in Europe simpler and more personalised.
The objective is straightforward: rather than requiring patients to navigate large numbers of hospitals, treatments and Treatment Packages themselves, MMG is developing intelligent tools capable of helping them identify the options most relevant to their individual circumstances.
A patient looking for a hip replacement, for example, will soon be able to tell MMG: “I want to be treated within six weeks. My budget is £9,000 and I would prefer not to fly for more than three hours.”
MMG’s technology can then use information held across the marketplace to help identify relevant Treatment Packages and enable the patient to compare factors including price, location and provider. As the platform develops, AI will increasingly help personalise this process around the individual patient’s requirements.
MMG is also implementing AI to support patients beyond the initial search. This includes helping patients understand what diagnostic information and medical records are required, identifying missing documentation, explaining the next stage of their treatment journey and providing increasingly personalised assistance as they progress from initial enquiry through hospital assessment, booking, treatment and follow-up.
AI also has the potential to make MMG’s extensive pricing data considerably more useful. Instead of simply seeing the price of an individual procedure, patients can increasingly be helped to understand how Treatment Packages compare with alternatives across Europe and with the cost of equivalent private treatment in the UK.
Importantly, MMG draws a clear distinction between using AI to help patients navigate healthcare and using it to practise medicine. AI does not replace doctors, diagnose conditions or determine whether somebody is clinically suitable for surgery. Those decisions remain firmly with appropriately qualified medical professionals at the patient’s chosen Accredited Healthcare Provider.
MMG’s approach is therefore to use AI where it can deliver the greatest benefit: removing complexity, improving information, making comparisons easier and supporting patients through what can otherwise be a daunting cross-border healthcare journey. The AI revolution identified by TBRC is already beginning. At MMG, it is becoming part of the infrastructure through which patients will search for, compare and access high-quality healthcare across Europe.
There is another remarkable statistic buried within the TBRC research.
Despite the medical tourism market already approaching $100 billion in 2025, its ten largest participants collectively accounted for just 1.18% of global revenue. The largest individual participant represented only 0.39%.
In other words, this is an enormous but extraordinarily fragmented global marketplace. That creates an opportunity not simply for hospitals, but for digital platforms capable of organising the market around the patient. For British consumers, that development could come at an important moment. Patients increasingly face a choice between waiting for treatment, paying high UK private healthcare prices or considering treatment elsewhere. Europe provides another option.
The extraordinary growth forecast by TBRC suggests millions of patients around the world are reaching the same conclusion: healthcare is becoming increasingly international. The next revolution will be making it as straightforward for patients to understand and navigate those choices as possible. That is precisely the problem My Medical Gateway was created to solve.
Explore your options with MMG
If you are considering private treatment, you don’t have to restrict your search to the UK. MMG allows you to explore Treatment Packages from selected Accredited Healthcare Providers across Europe, compare your options and receive support throughout your treatment journey.
Discover how much your treatment could cost in Europe and start exploring your options with My Medical Gateway today http://www.mymedicalgateway.com
Leave a Reply